MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

407

Employees407

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

407

Employees407

MNKD Key Statistics

Market cap

1.74B

Market cap1.74B

Price-Earnings ratio

60.02

Price-Earnings ratio60.02

Dividend yield

—

Dividend yield—

Average volume

3.23M

Average volume3.23M

High today

$5.77

High today$5.77

Low today

$5.62

Low today$5.62

Open price

$5.65

Open price$5.65

Volume

2.02M

Volume2.02M

52 Week high

$6.51

52 Week high$6.51

52 Week low

$3.38

52 Week low$3.38

Stock Snapshot

With a market cap of 1.74B, MannKind(MNKD) trades at $5.66. The stock has a price-to-earnings ratio of 60.02.

On 2026-02-14, MannKind(MNKD) stock traded between a low of $5.62 and a high of $5.77. Shares are currently priced at $5.66, which is +0.7% above the low and -1.8% below the high.

MannKind(MNKD) shares are trading with a volume of 2.02M, against a daily average of 3.23M.

In the last year, MannKind(MNKD) shares hit a 52-week high of $6.51 and a 52-week low of $3.38.

MNKD News

Simply Wall St 2h

How MannKind’s First Pediatric Afrezza Trial (INHALE-1ST) At MannKind Has Changed Its Investment Story

MannKind Corporation recently reported that it has enrolled the first pediatric patient in INHALE-1ST, a clinical study evaluating the safety and efficacy of Af...

TipRanks 5d

MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MannKind, with a price target of $10.00. Yun Zhong has given his Buy rating due t...

TipRanks 5d

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

MannKind (MNKD) announced that the first patient has been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza Inhalation Powder shortl...

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

More MNKD News

Simply Wall St 5d

Assessing MannKind Valuation After Afrezza Label Update Wins FDA Approval

Advertisement Why the Afrezza label change matters for MannKind (MNKD) The latest move around MannKind (MNKD) centers on the U.S. Food and Drug Administration...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.